Células - tronco e Derivados

Fresolimumab (GC1008) is a human monoclonal antibody targeting active TGFβ1, TGFβ2, TGFβ3, studied for cancer and focal segmental glomerulosclerosis.

TAK-441: oral Hedgehog signal blocker, potent anticancer, IC50=4.4 nM, reduces Gli1 mRNA & tumor growth.

β-catenin/CBP-IN-1 is a potent and selective inhibitor of CBP/β-catenin

Chroman 1 is a potent inhibitor of ROCK1 (IC50 = 52 pM) and ROCK2 (IC50 = 1 pM).

AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).

β-catenin-IN-2 is a potent inhibitor of β-catenin that can be used in colorectal cancer research.

KY02111 facilitates differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, maybe affect downstream of GSK3β and APC.

Avagacestat (BMS-708163) (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM,

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Simian OC/BGP. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Simian OC/BGP. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Simian OC/BGP, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Simian OC/BGP in the samples is then determined by comparing the OD of the samples to the standard curve.

WAY-297174 is a human protein kinase CK2 inhibitor with IC50 of > 33 μM.

GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.

AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.

GSK-3 inhibitor 3 is a selective, orally active, brain-permeable GSK-3 inhibitor that inhibits GSK-3α and GSK-3β with IC50s of 0.35 nM and 0.25 nM, respectively

YAP-TEAD-IN-3 inhibitor YAP/TAZ-TEAD interactions Avi-human TEAD (4217-434) YAP-TEAD-IN-3 inhibits YAP reporter gene expression and NCI-H2052 cell proliferation

GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).

VT104 is a potent and orally active YAP/TAZ inhibitor for cancer research.Cost-effective and quality-assured.

AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.

RKI1313 (RKI-1313) was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion

A 1070722: potent GSK-3 inhibitor, Ki = 0.6 nM for both α/β isoforms, crosses BBB, potential brain GSK-3 PET radiotracer.